Mercy participates in several clinical trials. Listed below are our current clincial trials protocols. Trials are continually being opened and closed. Please feel free to contact us about upcoming trials or if you any questions at all.
BREAST CANCER
BRE 133
Phase II Study of Ixabepilone and Cyclophosphamide as neoadjuvant therapy in HER2- Negative Breast Cancer
BRE 139
Phase II study of neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer.
BRE 154
A randomized, double-blind, placebo-controlled phase II trial of weekly paclitaxel/bevacizumab +/- everolimus as first-line chemotherapy for patients with HER2-negative metastatic breast cancer (MBC)
N063D (ALTTO)
A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence ant their combination in patients with HER2/ErbB2 positive primary breast cancer
SO500
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment
TAILORx Trial
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
TITAN (BRE 145)
A Randomized Trial of Ixempra vs. Taxol in Adjuvant Therapy of Triple-Negative Breast Cancer (TITAN)
WYETH 3004
A Randomized Double-Blind Placebo- Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/meu Overexpressed/Amplified Breast Cancer.
COLON CANCER
CALGB/SWOG C80405
A phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum.
LUNG CANCER
ECOG 1505
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) – IIIA Non-Small Cell Lung Cancer (NSCLC)
HSE-US-S130
Protocol H3E-US-S130: Randomized, open-label, phase 3 study of pemetrexed plus carboplatin followed by maintenance pemetrexed versus paclitaxel plus carboplatin an bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer of nonsquamous histology.
MULTIPLE MYELOMA
E1A06
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy
RENAL CANCER
ECOG 2805
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
To contact us with questions about clinical trials:
Mercy Oncology-Hematology Center
Clinical Trials Department
(207) 553-6866
Also See: